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Abstract
This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients
participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab.
The main findings show the T cell immunostimulatory properties of lenalidomide as the drug induced a decrease in the
percentage CD45RA+ naı¨ve T cells 3-fold while increasing the percentage HLA-DR+ activated T helper cells and percentage
total CD45RO+ CD8+ memory T cytotoxic cells, 2.6- and 2.1-fold respectively (p,0.0001). In addition, lenalidomide decreased
the percentage of circulating CD19+ B cells 2.6-fold (p,0.0001). Lenalidomide increased a modest, yet significant, 1.4-fold
change in the percentage of circulating natural killer cells. Our findings indicate that lenalidomide significantly activates T
cells, suggestive of an immunotherapeutic role for this drug in settings of maintenance therapy and tumor immunity.
Furthermore, reported for the first time is the effect of lenalidomide in combination with cetuximab on T cell function,
including increases in circulating naı¨ve and central memory T cells. In summary, lenalidomide and cetuximab have
significant effects on circulating immune cells in patients with colorectal carcinoma.
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Introduction
The immunomodulatory drug lenalidomide is an orally active
agent with significant activity in a range of hematologic disorders
including myelodysplastic syndromes (MDS), multiple myeloma
(MM), and non-Hodgkin’s lymphoma (NHL).
Lenalidomide has received US Food and Drug Administration
approval for the treatment of MM in patients who have received at
least one prior therapy, and for the treatment of transfusion-
dependent anemia in patients with International Prognostic
Scoring System-defined Low- or Intermediate-1-risk MDS with
a del(5q) cytogenetic abnormality, with or without additional
cytogenetic abnormalities. The molecular target of lenalidomide is
the protein cereblon (CRBN). CRBN is a ubiquitously expressed
protein and member of the cullin ring ligase 4 (CRL4) E3
ubiquitin ligase complex, and was identified as the primary
teratogenic target of thalidomide [1]. CRBN mediates both the
antiproliferative activities of lenalidomide in myeloma cells and T
cell activation [2,3]. The immunomodulatory effects of lenalido-
mide range across several cell types including both lymphoid and
myeloid lineages. In particular, in vitro data indicate lenalidomide
has activity in T cells, T regulatory cells (Tregs), B cells,
monocytes, natural killer (NK) T cells, and NK cells.
In anti-CD3 stimulated T cells, lenalidomide stimulates T cell
proliferation, and the production of interleukin (IL)-2, IL-12, and
interferon gamma [4,5]. In addition, lenalidomide has been shown
to inhibit Tregs proliferation and suppressor function in vitro [6]. In
advanced solid tumor patients treated with lenalidomide, naı¨ve
CD4+ helper and CD8+ cytotoxic T cells decreased, whereas
memory CD4+ helper memory T cells and CD8+ cytotoxic
memory cells increased [7]. Previous studies of the immunomod-
ulatory activity of lenalidomide have been undertaken in
hematological malignancies where immunological parameters
may be confounded by disease. However, there are limited data
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describing the immunomodulatory function of lenalidomide in
solid tumors.
In a clinical trial aimed to assess the efficacy and safety of
combination treatment with lenalidomide and cetuximab in KRAS
(v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)-mutant
metastatic colorectal cancer patients, we assessed 25 different
subpopulations of CD45+ immune cells (T cells, B cells, and NK
cells). This was a phase II multicenter, open-label trial comprising
a safety lead-in phase (phase IIa) to determine the maximum
tolerated dose, and a randomized proof of concept phase (phase
IIb) to determine the response rate of lenalidomide plus cetuximab
combination therapy. Phase IIa treatment comprised oral
lenalidomide (starting dose 25 mg/day) and intravenous cetux-
imab (400 mg/m2 followed by weekly 250 mg/m2) in 28-day
cycles. In phase IIb patients were randomized to either the phase
IIa treatment schedule of lenalidomide plus cetuximab combina-
tion therapy or lenalidomide 25 mg/day monotherapy. The
combination of lenalidomide and cetuximab appeared to be well
tolerated but did not have clinically meaningful activity in KRAS-
mutant metastatic colorectal cancer patients (12).
Materials and Methods
Patients, materials, and methods
This phase II, multicenter, open-label trial was conducted in
accordance with the ethical principles of the Declaration of
Helsinki and Good Clinical Practice, and according to the
International Conference on Harmonisation of Technical Re-
quirements for Registration of Pharmaceuticals for Human Use.
The study protocol, the proposed informed consent form, and
other information to subjects, were approved by the Comitato
Etico-Scientifico, Ospedale Niguarda Ca’ Granda, Milan, Italy
and properly constituted Institutional Review Boards/Indepen-
dent Ethics Committees of all participating institutions (Medical
Ethics Commission of the UZ KULeuven, Leuven, Belgium;
Clinical Research Ethics Committee of the University Hospital of
Vall d’Hebron, Barcelona, Spain; Scientific Ethics Committee of
the Ospedale Niguarda Ca’ Granda, Milan, Italy; Ethics
Committee Azienda Ospedaliero-Universitaria San Martino,
Genova, Italy; Ethics Committee Azienda Ospedaliero-Universi-
taria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di
Ancona, Torrette, Italy; Regional Ethics Review Board Stock-
holm, Karolinska Institute, Sweden; and Flinders Clinical
Research Ethics Committee, Southern Australia, Australia). The
study was registered at Clinicaltrials.gov with identifier
NCT01032291. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1.
Written informed consent was obtained from all participants
involved in the study. The study consisted of a safety lead-in phase
(phase IIa), in which the primary objective was to determine the
maximum tolerated dose of lenalidomide in combination with
cetuximab in subjects with KRAS-mutant mCRC, and a proof of
concept (POC) phase (phase IIb), in which the primary objective
was to determine the response rate in these subjects per the
Response Evaluation Criteria in Solid Tumors (RECIST) version
1.1. A total of 48 of 50 subjects who received drug were evaluated
for immune flow cytometric analysis.
Sample collection
Blood was collected at baseline (cycle 1 day 1 [C1D1]), cycle 2
day 1 (C2D1) and cycle 3 day 1 (C3D1) in either 5 ml Lavender/
Black Cyto-ChexH BCT glass tubes (Streck Innovations, Omaha,
NE, USA) or 2.6 ml yellow top acid citrate dextrose tubes
depending upon where the sample was received and maintained at
ambient temperature until flow cytometry was performed at
ICON Central Laboratories (Farmingdale, NY, USA) within
72 hours of sample collection. Stability analyses were conducted
during assay validation and supports up to 72 hours processing
time from sample collection to analysis. Antibodies (anti-CD3,
CD4, CD8, CD16, CD19, CD25, CD45, CD45RA, CD45RO,
CD62L, CD107a, CD127, granzyme B, and HLA-DR; BD
Biosciences, San Jose, CA, USA) and 100 ml of patient whole
blood were transferred to 12675 mm test tubes (BD FalconTM;
BD Biosciences) followed by gentle vortexing and 15 min
incubation at room temperature. To this, BD Pharm LyseTM
lysing solution (BD Biosciences) was added for 10 min. The tube
was centrifuged, washed in PBA (Dulbecco’s PBS/0.2%) and the
pellet was resuspended in PBA prior to analysis of B, T, and NK
cell subsets on a FACSCantoTM II flow cytometer (BD Bioscienc-
es). For intracellular protein staining, an additional permeabiliza-
tion step was added after the first addition of PBA with fixation-
permeabilization working solution (eBioscience, Inc., San Diego,
CA, USA), followed by two washes in permeabilization buffer
(eBioscience, Inc.), incubation with intracellular antibodies, and
another permeabilization buffer wash. Appropriate compensation
controls were included during each analysis. Each cell subset
population was reported as an absolute value per 1 mm3 of blood
or as a percentage of CD45+ cells.
Statistical analyses
To assess the changes in different immune cell populations at
C2D1 and C3D1 versus baseline, each of the 50 flow cytometry
measurements (i.e. one absolute cell count and one percentage
measurement for each of the 25 subpopulations of CD45+
immune cells) were first log2 transformed and a linear model
was then fitted with cycle number (i.e. C1D1, C2D1, and C3D1)
as an 3-level independent variable and patient as a blocking
variable using the R software package LIMMA [8]. Moderated t-
statistics and the corresponding p values for the two contrasts of
interested: C2D1 vs. C1D1 and C3D1 vs. C1D1 were computed
using the empirical Bayes method implemented in LIMMA. This
empirical Bayes step was carried out separately for absolute cell
counts and percentage measurements due to their very different
scales and variations. For each of the two contrasts, p-values were
later combined for absolute cell counts and percentage measure-
ments and were adjusted for multiple comparisons according to
the Benjamini-Hochberg method [9]. Adjusted p-values # 0.05
were considered statistically significant, which is equivalent to
controlling the false discovery rate at 5%. We carried out above
mentioned analyses separately in three different patient popula-
tions, i.e. 20 patients from the lenalidomide arm, 28 patients from
the lenalidomide plus cetuximab arm, or 48 patients from the two
arms combined (main analyses). We also carried out the analyses
in the three populations but with the 19 patients who were on a
concomitant medication which coded to an anatomic therapeutic
chemical category denoting a systemic or topical corticosteroid
removed (sensitivity analyses, results not shown). All statistical
analyses were carried out using R software [10].
Results
A total of 48 of 50 subjects who received study drug were
evaluable for peripheral blood immune cell analysis. The study
schema is shown in Figure 1 and the patient baseline character-
istics are summarized in Table 1. There were 20 subjects in the
lenalidomide arm and 28 in the lenalidomide plus cetuximab arm.
The biomarker and correlative analyses performed and the
Immune Effects of Lenalidomide and Cetuximab
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number of subjects included in each analysis is listed in Table S1.
The absolute number and percentage of 25 different subsets of T,
B, and NK cells were analyzed in these 48 patients and the cell
phenotypes are listed in Table 2. Cell populations with at least one
p-value # 0.05 in the comparisons of C2D1 and C3D1 versus
C1D1 in the lenalidomide monotherapy arm, the lenalidomide
plus cetuximab arm, and across all patients are shown in Tables 3,
4, and 5, respectively.
Figure 1. Study design and enrollment in patient groups. Study was terminated before the expansion part of phase IIb. *One patient was
randomized to the lenalidomide monotherapy group but discontinued before taking any study drug and was therefore excluded from the analyses.
AE, adverse event; ITT, intention to treat; PD, progressive disease.
doi:10.1371/journal.pone.0080437.g001
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The major findings include four immune cell populations with
highly significant (p # 0.0001) changes from C1D1 (baseline) to
C2D1 and to C3D1 in both the absolute number and the
percentage of cells measured in both treatment arms. The changes
in these populations are shown in Figure 2 and include an increase
in total memory T cytotoxic cells and activated T helper cells, and
a decrease in B cells and total naı¨ve T helper cells. The changes in
the remaining cell subsets across all subjects are shown in Figure
S1.
Table 1. Patient baseline characteristics.
Lenalidomide (n =21) Lenalidomide plus cetuximab (n =29)
Median age, years (range) 54 (38–75) 58 (31–70)
Sex Male 12 (57.1%) 16 (55.2%)
Female 9 (42.9%) 13 (44.8%)
ECOG PS score 0 10 (47.6%) 20 (69.0%)
1 10 (47.6%) 9 (31.0%)
2 1 (4.8%) 0
Concomitant steroids 7 (33%) 12 (41%)
Previous lines of systemic anticancer therapy 2 5 (23.8%) 9 (31.0%)
3 4 (19.0%) 6 (20.7%)
.3 12 (57.1%) 14 (48.2%)
ECOG PS, Eastern Cooperative Oncology Group performance status.
doi:10.1371/journal.pone.0080437.t001
Table 2. Cell surface marker phenotype of each immune cell subset assessed by immunoflow cytometry.
Subset Cell type (phenotype)
WBC Lymphocytes (CD45)
Lymphocytes Total T cells (CD45+ CD3+)
T helper cells (CD45+ CD3+ CD4+ CD82)
T cytotoxic cells (CD45+ CD3+ CD42 CD8+)
NK cells (CD45+ CD32 CD16+56+)
B cells (CD45+ CD32 CD19+)
Total naı¨ve T helper cells (CD45+ CD3+ CD4+ CD82 CD45RA+ CD45RO2)
Total memory T helper cells (CD45+ CD3+ CD4+ CD82 CD45RA2 CD45RO+)
Total naı¨ve T cytotoxic cells (CD45+ CD3+ CD42 CD8+ CD45RA+ CD45RO2)
Total memory T cytotoxic cells (CD45+ CD3+ CD42 CD8+ CD45RA2 CD45RO+)
T helper Activated T helper cells (CD45+ CD3+ CD4+ CD82 HLADR+)
Effector memory T helper cells (CD45+ CD3+ CD4+ CD82 CD45RA2 62L2)
Effector T helper cells (CD45+ CD3+ CD4+ CD82 CD45RA+ 62L2)
Central memory T helper cells (CD45+ CD3+ CD4+ CD82 CD45RA2 62L+)
Naı¨ve T helper cells (CD45+ CD3+ CD4+ CD82 CD45RA+ 62L+)
CD40L+ T helper cells (CD3+ CD4+ CD154+)
T regulatory cells (CD3+ CD4+ FOX P3+ CD1272 CD25++)
T cytotoxic Activated T cytotoxic cells (CD45+ CD3+ CD42 CD8+ HLADR+)
Effector memory T cytotoxic cells (CD45+ CD3+ CD42 CD8+ CD45RA2 62L2)
Effector T cytotoxic cells (CD45+ CD3+ CD42 CD8+ CD45RA+ 62L2)
Central memory T cytotoxic cells (CD45+ CD3+ CD42 CD8+ CD45RA2 62L+)
Naı¨ve T cytotoxic cells (CD45+ CD3+ CD42 CD8+ CD45RA+ 62L+)
NK cells CD107a+ NK cells (CD45+ CD32 CD16+ CD56+ CD107a+)
Granzyme B+ NK cells (CD45+ CD32 CD16+ CD56+ Granzyme B+)
NKG2D+ NK cells (CD45+ CD32 CD16+ CD56+ CD314+)
NK, natural killer; WBC, white blood cells.
doi:10.1371/journal.pone.0080437.t002
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Immunomodulatory effects in subjects receiving
lenalidomide only
In the lenalidomide only arm (n = 20), 12 T cell populations,
total NK cells, total B cells, and total lymphocyte cell populations
(either percentage or absolute count) were significantly changed
(p#0.05) in either C2D1 or C3D1 versus C1D1, or both. These T
cell populations, starting with the most significant, include total
naı¨ve T helper cells, activated T helper cells, activated T cytotoxic
cells, T regulatory cells, total naı¨ve T cytotoxic cells, effector T
helper cells, effector T cytotoxic cells, total memory T cytotoxic
cells, effector memory T cytotoxic cells, T helper cells, T cytotoxic
cells, and total T cells. Absolute and percentage B cells decreased
1.78- to 3.41-fold. The percentage of NK cells significantly
increased at C2D1 by 1.4-fold across subjects taking lenalidomide
only. The absolute lymphocytes significantly decreased 1.36-fold
across subjects taking lenalidomide only (Table 3). Of note,
contrary to in vitro data showing lenalidomide inhibits Tregs
expansion [11], lenalidomide significantly increased the percent-
age of Tregs by 4- to 12-fold.
Immunomodulatory effects in subjects receiving
lenalidomide plus cetuximab
In the lenalidomide plus cetuximab arm (n = 28), 15 T cell
populations, 1 NK cell population, total B cells, and total
lymphocyte cell populations (either percentage or absolute count)
were significantly changed (p # 0.05) in either C2D1 or C3D1
versus C1D1, or both. These T cell populations, starting with the
most significant, include activated T helper cells, total memory T
cytotoxic cells, total naı¨ve T helper cells, total naı¨ve T cytotoxic
cells, effector memory T cytotoxic cells, activated T cytotoxic cells,
effector T cytotoxic cells, central memory T cytotoxic cells,
effector T helper cells, effector memory T helper cells, total
memory T helper cells, central memory T helper cells, naı¨ve T
cytotoxic cells, T cytotoxic cells, and naı¨ve T helper cells. Absolute
and percentage B cells decreased 2.01- to 3.6-fold. The percentage
of granzyme B+ NK cells significantly increased at C2D1 by 1.15-
fold and at C3D1 by 1.25-fold in subjects taking lenalidomide plus
cetuximab. The percentage of lymphocytes significantly increased
1.11- to 1.45-fold in subjects taking lenalidomide plus cetuximab
(Table 4). Of these, the following seven subpopulations were
significantly modulated in the lenalidomide plus cetuximab arm,
but not in the lenalidomide arm only: central memory T cytotoxic
cells, effector memory T helper cells, total memory T helper cells,
central memory T helper cells, naı¨ve T cytotoxic cells, naı¨ve T
helper cells, and granzyme B+ NK cells. Of note, addition of
cetuximab to lenalidomide did not result in an increase in Tregs as
was observed by lenalidomide alone.
Table 3. Significantly regulated cell populations in the lenalidomide monotherapy arm.
C2D1 versus C1D1 C3D1 versus C1D1
FDR adjusted p-value FC FDR adjusted p-value FC
T cells Abs total naı¨ve T helper cells ,0.0001 24.02 0.0743 22.33
% Total naı¨ve T helper cells ,0.0001 23 0.0094 22.13
Abs activated T helper cells 0.0135 1.78 0.644 1.28
% Activated T helper cells ,0.0001 2.65 0.0231 1.81
Abs activated T cytotoxic cells 0.0226 1.58 0.436 1.42
% Activated T cytotoxic cells ,0.0001 1.91 0.0094 1.75
Abs total naı¨ve T cytotoxic cells 0.0008 22.16 0.227 21.64
% Total naı¨ve T cytotoxic cells 0.0001 21.6 0.0511 21.49
Abs effector T helper cells 0.0025 23.17 0.0094 26.85
% Effector T helper cells 0.0181 22.32 0.0147 25.5
Abs effector T cytotoxic cells 0.0099 21.56 0.129 21.64
% Effector T cytotoxic cells 0.0005 21.31 0.0263 21.34
Abs total memory T cytotoxic cells 0.0242 1.51 0.162 1.66
% Total memory T cytotoxic cells 0.0002 2.08 0.0545 1.87
Abs effector memory T cytotoxic cells 0.035 1.71 0.812 1.19
% Effector memory T cytotoxic cells 0.0013 2.08 0.38 1.48
% T cytotoxic cells 0.017 1.13 0.812 1.04
Abs T regulatory cells* 0.0047 2.28 0.0094 5.61
% T regulatory cells* 0.0018 4.4 0.0094 12.1
Abs T helper cells* 0.0199 21.49 0.812 21.1
Abs total T cells* 0.0318 21.38 0.812 21.08
B cells Abs B cells 0.0001 23.41 0.191 21.93
% B cells ,0.0001 22.59 0.116 21.78
NK cells % NK cells* 0.0318 1.4 1 21.01
Lymphocytes Abs lymphocytes 0.0378 21.36 0.812 21.1
*Cell populations that are unique to the lenalidomide monotherapy arm only.
Abs, absolute; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; C3D1, cycle 3 day 1; FC, fold change; NK, natural killer.
doi:10.1371/journal.pone.0080437.t003
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Immunomodulatory effects in all subjects
Across all 48 subjects, 16 T cell populations, 1 NK cell
populations, total B cells, and total lymphocytes (either percentage
or absolute count) were significantly modulated (p # 0.05) in
either C2D1 or C3D1 versus C1D1, or both. These T cell
populations, starting with the most significant, include activated T
helper cells, total naı¨ve T helper cells, total memory T cytotoxic
cells, total naı¨ve T cytotoxic cells, activated T cytotoxic cells,
effector memory T cytotoxic cells, effector T helper cells, effector
T cytotoxic cells, central memory T cytotoxic cells, effector
memory T helper cells, T regulatory cells, central memory T
helper cells, naı¨ve T cytotoxic cells, total memory T helper cells, T
cytotoxic cells, and naı¨ve T helper cells. Absolute and percentage
B cells decreased between 2.35- and 3.05-fold. The percentage of
granzyme B+ NK cells significantly increased 1.21-fold at C3D1,
whereas the percentage of lymphocytes increased 1.33-fold at
C3D1 across all subjects (Table 5).
Effects of concomitant immunosuppressive agents
Overall, 19 of the 48 patients were identified as being on either
daily or intermittent, concomitant systemic or topical corticoste-
roids. Of these 19 patients on concomitant corticosteroids for
various periods of time, 5 received dexamethasone (ranging from
8 mg daily to 10 mg weekly), 10 received prednisone (ranging
from 25 mg twice-daily to 4 mg daily), 5 received betamethasone
(ranging from 4 mg daily to 4 mg as needed), and 5 received
ultrapotent topical corticosteroids. To rule out any possible effect
of these immunosuppressive corticosteroid therapies on the
expression of any of the cell populations, a sensitivity analysis
was performed excluding the patients on concomitant immuno-
suppressive medications and the analysis was reperformed. In the
Table 4. Significantly regulated cell populations in the lenalidomide plus cetuximab arm.
C2D1 versus C1D1 C3D1 versus C1D1
FDR adjusted
p-value FC
FDR adjusted
p-value FC
T cells Abs total naı¨ve T helper cells ,0.0001 22.42 0.0002 23.13
% Total naı¨ve T helper cells ,0.0001 22.6 0.0003 22.71
Abs activated T helper cells ,0.0001 2.15 0.0526 1.45
% Activated T helper cells ,0.0001 2.33 ,0.0001 2.16
Abs activated T cytotoxic cells 0.0046 1.83 0.306 1.34
% Activated T cytotoxic cells 0.0001 1.77 0.0081 1.7
Abs total naı¨ve T cytotoxic cells 0.0352 21.34 0.0166 21.56
% Total naı¨ve T cytotoxic cells ,0.0001 21.43 0.0029 21.34
Abs effector T helper cells 0.246 21.7 0.0047 25.15
% Effector T helper cells 0.267 21.59 0.0129 23.64
Abs effector T cytotoxic cells 0.4 21.2 0.0166 21.87
% Effector T cytotoxic cells 0.0196 21.25 0.0043 21.48
Abs total memory T cytotoxic cells ,0.0001 2.32 0.0404 1.51
% Total memory T cytotoxic cells ,0.0001 2.22 0.0029 1.79
Abs effector memory T cytotoxic cells 0.0046 1.71 0.782 1.08
% Effector memory T cytotoxic cells ,0.0001 1.65 0.0265 1.37
% T cytotoxic cells 0.0289 1.15 0.159 1.13
Abs central memory T cytotoxic cells* 0.321 1.65 0.0047 6.17
% Central memory T cytotoxic cells* 0.416 2.79 0.0112 62.8
Abs effector memory T helper cells* 0.678 1.11 0.0166 22.08
Abs total memory T helper cells* 0.0211 1.35 0.794 21.05
% Total memory T helper cells* 0.0096 1.27 0.346 1.12
Abs central memory T helper cells* 0.329 1.95 0.0149 8.21
% Central memory T helper cells* 0.416 2.29 0.0175 20.3
Abs naı¨ve T cytotoxic cells* 0.678 1.29 0.0166 6.13
% Naı¨ve T cytotoxic cells* 0.64 1.58 0.0325 11.9
Abs naı¨ve T helper cells* 0.722 1.28 0.0325 6.86
B cells Abs B cells 0.0054 22.01 0.0005 23.6
% B cells 0.0018 22.17 0.0011 23.16
NK cells % Granzyme B+ NK cells* 0.114 1.15 0.0374 1.25
Lymphocytes % Lymphocytes 0.469 1.11 0.0337 1.45
*Cell populations that are unique to the lenalidomide plus cetuximab arm only.
Abs, absolute; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; C3D1, cycle 3 day 1; FC, fold change; NK, natural killer.
doi:10.1371/journal.pone.0080437.t004
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sensitivity analyses, the same four cell populations consistently
showed significant (p # 0.0001) changes from C1D1 (baseline) to
C2D1 or C3D1 in both measurements assessed (absolute number
and percentage) signifying these effects are not due to steroid
usage. In fact, patients on immunosuppressive concomitant
medications had similar magnitude of immune effects (T cell
activation and B cell inhibition), and a greater number of immune
cell subsets modulated compared with patients not on concomitant
therapies. In addition, an analysis of immune changes in
concomitant steroid users versus nonusers was performed and
the results were comparable (data not shown).
Correlations of immunomodulatory effects with clinical
response
As reported by Siena et al. [12], 8 patients were enrolled into
the phase IIa maximum tolerated dose portion of the study and 43
patients were enrolled into the phase IIb POC portion. Best
response was stable disease (SD) in 9 patients and study enrollment
was terminated prematurely due to lack of efficacy in any of the
treatment arms and failure to achieve the planned response
objective. There were no significant (p # 0.05) correlations
between changes from baseline (C1D1) to C2D1 or C3D1 of any
immune cell population in overall survival (OS) regardless of
treatment arm (data not shown).
Table 5. Significantly regulated cell populations in all subjects.
C2D1 versus C1D1 C3D1 versus C1D1
FDR adjusted
p-value FC
FDR adjusted
p-value FC
T cells Abs total naı¨ve T helper cells ,0.0001 23.03 ,0.0001 22.94
% Total naı¨ve T helper cells ,0.0001 22.77 ,0.0001 22.53
Abs activated T helper cells ,0.0001 1.98 0.0567 1.38
% Activated T helper cells ,0.0001 2.47 ,0.0001 2.06
Abs activated T cytotoxic cells 0.0001 1.72 0.132 1.35
% Activated T cytotoxic cells ,0.0001 1.83 ,0.0001 1.72
Abs T regulatory cells 0.0105 1.88 0.0027 3.03
% T regulatory cells 0.0098 3.41 0.0162 5.21
Abs total naı¨ve T cytotoxic cells ,0.0001 21.66 0.0038 21.63
% Total naı¨ve T cytotoxic cells ,0.0001 21.5 ,0.0001 21.39
Abs effector T helper cells 0.0021 22.23 ,0.0001 25.84
% Effector T helper cells 0.0097 21.87 0.0001 24.24
Abs effector T cytotoxic cells 0.0173 21.34 0.0015 21.82
% Effector T cytotoxic cells ,0.0001 21.27 ,0.0001 21.44
Abs total memory T cytotoxic cells ,0.0001 1.92 0.0148 1.52
% Total memory T cytotoxic cells ,0.0001 2.16 ,0.0001 1.81
Abs effector memory T cytotoxic cells 0.0001 1.71 0.622 1.11
% Effector memory T cytotoxic cells ,0.0001 1.83 0.0148 1.42
% T cytotoxic cells 0.0005 1.15 0.0979 1.1
Abs central memory T cytotoxic cells 0.144 1.55 0.0003 4.46
% Central memory T cytotoxic cells 0.253 2.5 0.0037 25.8
Abs effector memory T helper cells 0.724 21.07 0.0017 22.1
% Effector memory T helper cells 0.182 1.15 0.0163 21.43
% Total memory T helper cells 0.0005 1.24 0.272 1.1
Abs central memory T helper cells 0.179 1.8 0.0038 5.75
% Central memory T helper cells 0.144 2.6 0.0037 14
Abs naı¨ve T cytotoxic cells 0.724 1.16 0.0052 4.32
% Naı¨ve T cytotoxic cells 0.531 1.49 0.0163 7.63
Abs naı¨ve T helper cells 0.956 21.02 0.038 3.87
% Naı¨ve T helper cells 0.843 21.14 0.0429 6.21
B cells Abs B cells ,0.0001 22.54 ,0.0001 23.05
% B cells ,0.0001 22.35 ,0.0001 22.66
NK cells % Granzyme B+ NK cells 0.179 1.09 0.0284 1.21
Lymphocytes % Lymphocytes 0.918 21.01 0.0291 1.33
Abs, absolute; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; C3D1, cycle 3 day 1; FC, fold change; NK, natural killer.
doi:10.1371/journal.pone.0080437.t005
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Figure 2. Significant changes in number in four immune cell subsets. Significant (p # 0.0001) changes in percentage and absolute number
in four immune cell subsets from cycle 1 day 1 (C1D1) to cycle 2 day 1 (C2D1) or cycle 3 day 1 (C3D1) in all subjects. The upper edge of the box
denotes the 75th percentile whereas the lower edge denotes the 25th percentile. The line inside each box is the median. The lines extend to the
maximum and minimum values excluding outliers. The gray lines denote individual subject data. Abs, absolute.
doi:10.1371/journal.pone.0080437.g002
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Discussion
Lenalidomide is approved for use in both MM and MDS, and
has reported clinical activity in chronic lymphocytic leukemia
(CLL) and NHL [13,14]. Much of the activity of lenalidomide in
these hematological malignancies has been attributed to cell
autonomous killing effects. In a clinical trial reported by Siena et al
(12) aimed to assess the efficacy and safety of combination
treatment with lenalidomide and cetuximab in KRAS (v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog)-mutant metastatic
colorectal cancer patients, we assessed 25 different subpopulations
of CD45+ immune cells (T cells, B cells, and NK cells) in this
patient population that does not have confounding hematological
abnormalities. The major findings are significant (p # 0.0001)
changes from baseline to C2D1 and to C3D1 in the following four
lymphocyte populations: B cells (decreased), activated T helper
cells (increased), total memory T cytotoxic cells (increased), and
total naı¨ve T helper cells (decreased). One potential clinical
relevance of these findings implicate lenalidomide is an activator of
T cells which may play a role in its anti-tumor activity. In addition,
the downregulation of B cell counts may be linked to its activity in
B cell malignancies. These effects were detected in both treatment
arms. As all subjects were treated with lenalidomide, these changes
may be ascribed to the pharmacodynamic effects of lenalidomide.
The correlative analyses showed that changes in the cell
populations (absolute number or percentage) tested did not
correlate with treatment arm, response per RECIST version 1.1
criteria, or OS. The clinical responses from this study are reported
in detail by Siena et al. [12].
Furthermore, lenalidomide plus cetuximab had remarkable
effects (up to 60-fold increases) in central memory and naı¨ve T
cells suggestive that cetuximab itself may play a role in T cell
activation and function. Similar effects were reported by Botta et al.
[15] in a cetuximab-based polychemotherapy regimen in patients
with advanced mCRC. This is the first study, to our knowledge, to
report a comprehensive profile of the circulating immune cell
subsets in subjects receiving lenalidomide and to show evidence of
the T cell activating function of lenalidomide plus cetuximab.
Patients with mCRC administered with the B cell depleting
agent rituximab have shown both regression of metastases and
achievement of SD [16]. In our study, although the majority of
patients treated with lenalidomide showed significant decreases in
B cells, this pharmacodynamic effect did not correlate with OS.
Similarly, a related analog pomalidomide, has been reported to
reduce CD19+ peripheral blood B cells in patients with MM
receiving alternate day dosing of 1–10 mg [17].
Preclinical and clinical data indicate that lenalidomide activates
T cells. Bartlett et al. [7] showed that in patients with advanced
solid tumors, treatment with lenalidomide for 4–5 weeks decreased
the percentages of naı¨ve helper and cytotoxic T cells, and
increased the percentages of memory helper and cytotoxic cells—
both of these findings were confirmed in the present study.
Pomalidomide has also been reported to increase peripheral blood
CD3+ and CD8+ T cells in patients with MM [17].
In vitro, lenalidomide inhibits Tregs; however, in this study an
upward trend (p,0.05) in both absolute number and percentage
of circulating Tregs in peripheral blood was observed at both
C2D1 and C3D1 in subjects taking lenalidomide alone. Similarly,
the level of circulating Tregs was increased in patients with MM
within 2 weeks of receiving lenalidomide [18]. These patients with
MM showed a significant increase in HLA-DR+ T cells (both
CD4+ and CD8+ subsets). The increase in CD4+FOX-P3+
regulatory T cells was observed after 9 cycles (9 months) of
lenalidomide maintenance therapy. Therefore, the increase in
regulatory T cells may be a late response to increased effector T
cell numbers and activity.
The activation of NK cells by lenalidomide has been shown in
vitro by both increased NK cell cytokine production as well as in
functional studies. In a peripheral blood mononuclear cell/tumor
cell co-culture model, T cell co-stimulation leads to enhanced NK
cell-mediated lysis of various tumor cells, including prostate and
ovarian cancer cells [19]. Lenalidomide enhances NK cell and
monocyte-mediated antibody dependent cellular cytotoxicity
(ADCC) of rituximab against a variety of hematological cell lines
in vitro, including NHL and B-CLL [20], as well as enhancing NK
cell mediated lysis of cetuximab and trastuzumab coated colorectal
and breast cancer cells, respectively [21]. In the present study,
although no significant effects were observed in changes of
peripheral NK cells, a non-significant increasing trend was observed
in both absolute number and percentage of total NK cells and
activated NK cells (granzyme B+ and NKD+) after 28-days of dosing
versus baseline. These data do not preclude the possibility that
lenalidomide increased NK cells and ADCC at the site of the tumor.
Our data previously indicated that dexamethasone antagonizes the
stimulatory capacity of lenalidomide on both NK and T cells in vitro
[22]. The effect of dexamethasone on lenalidomide activation of
NK cells in patients with MM indicates that although the number of
circulating NK cells increases after lenalidomide plus dexametha-
sone treatment, the cytotoxic capacity of NK cells becomes
impaired due to dexamethasone-induced suppression of IL-2
production from CD4+ T cells [23]. To control for possible
pharmacodynamic effects of concomitant steroid use on changes
from baseline on the populations of CD45+ cells analyzed in the
present study, sensitivity analyses were performed to exclude data
for subjects who had used a systemic corticosteroid or a potent
topical corticosteroid during the study. The results of the sensitivity
analyses were consistent with those of the main analysis, indicating
that the inhibition of B cells is a true pharmacodynamic effect of
lenalidomide and this effect is not confounded by intermittent
concomitantly administered immunosuppressive therapies. The
doses and frequency of dexamethasone taken in this study were
insufficient to antagonize the T cell effects of lenalidomide,
consistent with previous findings that low-dose dexamethasone
allows for greater T cell activation by lenalidomide.
In conclusion, despite preclinical evidence, the present clinical
data from Siena et al (12) suggest the modulating effect of
lenalidomide is unable to overcome primary resistance of KRAS-
mutant mCRC to EGFR targeted inhibition by cetuximab.
Importantly, these data illustrate the immunomodulatory effects
of lenalidomide which helps in understanding the drug’s mech-
anism and potential applicability to other tumor types.
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